{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:56:05Z","timestamp":1759334165566,"version":"build-2065373602"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-025-13403-3","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:58:33Z","timestamp":1759229913000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of deucravacitinib versus apremilast of moderate-to-severe plaque psoriasis in China"],"prefix":"10.1186","volume":"25","author":[{"given":"Bingying","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rumeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaofei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"9997","key":"13403_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/s0140-6736(14)61909-7","volume":"386","author":"WH Boehncke","year":"2015","unstructured":"Boehncke WH, Sch\u00f6n MP. Psoriasis. Lancet. 2015;386(9997):983\u201394. https:\/\/doi.org\/10.1016\/s0140-6736(14)61909-7.","journal-title":"Lancet"},{"key":"13403_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/ptt.S64950","volume":"6","author":"N Ayala-Font\u00e1nez","year":"2016","unstructured":"Ayala-Font\u00e1nez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases. Psoriasis (Auckl). 2016;6:7\u201332. https:\/\/doi.org\/10.2147\/ptt.S64950.","journal-title":"Psoriasis (Auckl)"},{"issue":"10275","key":"13403_CR3","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/s0140-6736(21)00184-7","volume":"20","author":"K Ghoreschi","year":"2021","unstructured":"Ghoreschi K, Balato A, Enerb\u00e4ck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;20(10275):754\u201366. https:\/\/doi.org\/10.1016\/s0140-6736(21)00184-7.","journal-title":"Lancet"},{"issue":"3","key":"13403_CR4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","volume":"140","author":"JE Hawkes","year":"2017","unstructured":"Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645\u201353. https:\/\/doi.org\/10.1016\/j.jaci.2017.07.004.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"13403_CR5","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1007\/s13555-023-01014-x","volume":"13","author":"G Girolomoni","year":"2023","unstructured":"Girolomoni G, Savage L, Gisondi P, et al. Increasing access to effective systemic treatments in patients with Moderate-to-Severe psoriasis: narrative review. Dermatol Ther (Heidelb) Oct. 2023;13(10):2171\u201385. https:\/\/doi.org\/10.1007\/s13555-023-01014-x.","journal-title":"Dermatol Ther (Heidelb) Oct"},{"issue":"1","key":"13403_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-024-09591-5","volume":"6","author":"Y Xiao","year":"2025","unstructured":"Xiao Y, Hong X, Neelagar R, Mo H. Age-standardized incidence, prevalence, mortality rates and future projections of autoimmune diseases in China: a systematic analysis based on GBD 2021. Immunol Res. 2025;6(1): 26. https:\/\/doi.org\/10.1007\/s12026-024-09591-5.","journal-title":"Immunol Res"},{"issue":"1","key":"13403_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/12034754241293090","volume":"29","author":"F Yuan","year":"2025","unstructured":"Yuan F, Cao L, Lu L, Wang S, Jiang F, Lin B. Epidemiological analysis of psoriasis in China from 2020 to 2022. J Cutan Med Surg. 2025;29(1):29\u201332. https:\/\/doi.org\/10.1177\/12034754241293090.","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"13403_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG, Psoriasis. Which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol Jan. 2019;80(1):27\u201340. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.057.","journal-title":"J Am Acad Dermatol Jan"},{"issue":"5","key":"13403_CR9","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: sect.\u00a01. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol May. 2008;58(5):826\u201350. https:\/\/doi.org\/10.1016\/j.jaad.2008.02.039.","journal-title":"J Am Acad Dermatol May"},{"issue":"19","key":"13403_CR10","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"19","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology. Clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;19(19):1945\u201360. https:\/\/doi.org\/10.1001\/jama.2020.4006.","journal-title":"JAMA"},{"key":"13403_CR11","first-page":"791","volume":"52","author":"X Chen","year":"2019","unstructured":"Chen X, Zheng L, Zhang H, et al. Disease burden and quality of life in patients with psoriasis: an internet-based questionnaire. Chin J Dermatology. 2019;52:791\u20135.","journal-title":"Chin J Dermatology"},{"issue":"Dec","key":"13403_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-021-01902-w","volume":"24","author":"H Zhong","year":"2021","unstructured":"Zhong H, Yang H, Mao Z, Chai X, Li S. Impact of moderate-to-severe psoriasis on quality of life in China: a qualitative study. Health Qual Life Outcomes. 2021;24(Dec): 271. https:\/\/doi.org\/10.1186\/s12955-021-01902-w.","journal-title":"Health Qual Life Outcomes"},{"key":"13403_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci Mar. 2019. https:\/\/doi.org\/10.3390\/ijms20061475.","journal-title":"Int J Mol Sci Mar"},{"issue":"12","key":"13403_CR14","first-page":"1033","volume":"54","author":"Chinese Society of Dermatology CDA, Dermatology & Venereology Specialized Committee of Chinese Association of Integrative Medicine","year":"2021","unstructured":"Chinese Society of Dermatology CDA, Dermatology & Venereology Specialized Committee of Chinese Association of Integrative Medicine. Guidelines for the treatment of psoriasis with biologic agents in China. Chin J Dermatology. 2021;54(12):1033\u201347.","journal-title":"Chin J Dermatology"},{"issue":"11","key":"13403_CR15","doi-asserted-by":"publisher","first-page":"976","DOI":"10.35541\/cjd.20240294","volume":"57","author":"Chinese Society of Dermatology CDA DVSCoCAoIM","year":"2024","unstructured":"Chinese Society of Dermatology CDA DVSCoCAoIM. Guidelines for the treatment of psoriasis with biologics and small-molecule drugs in China (2024). Chin J Dermatology. 2024;57(11):976\u201397. https:\/\/doi.org\/10.35541\/cjd.20240294.","journal-title":"Chin J Dermatology"},{"issue":"11","key":"13403_CR16","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1007\/s13555-023-01041-8","volume":"13","author":"J Zhang","year":"2023","unstructured":"Zhang J, Xia Z, Guo W, et al. Cost-Effectiveness of Secukinumab versus other biologics in the treatment of Moderate-to-Severe plaque psoriasis: the Chinese healthcare system perspective. Dermatol Ther (Heidelb) Nov. 2023;13(11):2681\u201396. https:\/\/doi.org\/10.1007\/s13555-023-01041-8.","journal-title":"Dermatol Ther (Heidelb) Nov"},{"key":"13403_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae406","author":"J Zhang","year":"2024","unstructured":"Zhang J, Ding Y, Wang P, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan, and South Korea with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. Br J Dermatol Oct. 2024. https:\/\/doi.org\/10.1093\/bjd\/ljae406.","journal-title":"Br J Dermatol Oct"},{"issue":"2","key":"13403_CR18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jaad.2017.01.052","volume":"77","author":"J Crowley","year":"2017","unstructured":"Crowley J, Tha\u00e7i D, Joly P, et al. Long-term safety and tolerability of Apremilast in patients with psoriasis: pooled safety analysis for \u2265\u2009156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol Aug. 2017;77(2):310\u2013e3171. https:\/\/doi.org\/10.1016\/j.jaad.2017.01.052.","journal-title":"J Am Acad Dermatol Aug"},{"key":"13403_CR19","doi-asserted-by":"publisher","first-page":"1180170","DOI":"10.3389\/fimmu.2023.1180170","volume":"14","author":"Y Xu","year":"2023","unstructured":"Xu Y, Li Z, Wu S, Guo L, Jiang X. Oral small-molecule tyrosine kinase 2 and phosphodiesterase 4 inhibitors in plaque psoriasis: a network meta-analysis. Front Immunol. 2023;14:1180170. https:\/\/doi.org\/10.3389\/fimmu.2023.1180170.","journal-title":"Front Immunol"},{"issue":"8","key":"13403_CR20","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/jdv.19925","volume":"38","author":"B Strober","year":"2024","unstructured":"Strober B, Blauvelt A, Warren RB, et al. Deucravacitinib in moderate-to-severe plaque psoriasis: pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). J Eur Acad Dermatol Venereol. 2024;38(8):1543\u201354. https:\/\/doi.org\/10.1111\/jdv.19925.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"13403_CR21","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1080\/03007995.2018.1428542","volume":"34","author":"P Foley","year":"2018","unstructured":"Foley P, Garrett S, Ryttig L. A cost-effectiveness analysis of calcipotriol plus betamethasone dipropionate aerosol foam versus gel for the topical treatment of plaque psoriasis. Curr Med Res Opin Jul. 2018;34(7):1277\u201383. https:\/\/doi.org\/10.1080\/03007995.2018.1428542.","journal-title":"Curr Med Res Opin Jul"},{"issue":"5","key":"13403_CR22","first-page":"416","volume":"14","author":"PRC NHCot","year":"2024","unstructured":"PRC NHCot. Statistical bulletin of China\u2019s health development in 2023. Chin J Viral Dis. 2024;14(5):416\u201324.","journal-title":"Chin J Viral Dis"},{"issue":"7","key":"13403_CR23","doi-asserted-by":"publisher","first-page":"573","DOI":"10.35541\/cjd.20220839","volume":"56","author":"Committee on Psoriasis CSoD","year":"2023","unstructured":"Committee on Psoriasis CSoD. Guideline for the diagnosis and treatment of psoriasis in China (2023 edition). Chin J Dermatology. 2023;56(7):573\u2013625. https:\/\/doi.org\/10.35541\/cjd.20220839","journal-title":"Chin J Dermatology"},{"key":"13403_CR24","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.4688","author":"AW Armstrong","year":"2025","unstructured":"Armstrong AW, Lebwohl M, Warren RB, et al. Safety and efficacy of Deucravacitinib in moderate to severe plaque psoriasis for up to 3 years: an open-label extension of randomized clinical trials. JAMA Dermatol. 2025(1). https:\/\/doi.org\/10.1001\/jamadermatol.2024.4688.","journal-title":"JAMA Dermatol"},{"issue":"7","key":"13403_CR25","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1111\/1346-8138.16766","volume":"50","author":"M Kishimoto","year":"2023","unstructured":"Kishimoto M, Komine M, Kamiya K, Sugai J, Kuwahara A, Ohtsuki M. Four-year drug survival of Apremilast in patients with psoriasis. J Dermatol. 2023;50(7):960\u20133. https:\/\/doi.org\/10.1111\/1346-8138.16766.","journal-title":"J Dermatol"},{"key":"13403_CR26","unstructured":"National Bureau of Statistics of China. Accessed 5 Feb 2025.\u00a0https:\/\/www.stats.gov.cn\/english\/Statisticaldata\/yearbook\/"},{"key":"13403_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph15122622","author":"YX Dai","year":"2018","unstructured":"Dai YX, Hsu MC, Hu HY, et al. The risk of mortality among psoriatic patients with varying severity: a nationwide population-based cohort study in Taiwan. Int J Environ Res Public Health Nov. 2018. https:\/\/doi.org\/10.3390\/ijerph15122622.","journal-title":"Int J Environ Res Public Health Nov"},{"issue":"2","key":"13403_CR28","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/ije\/dym062","volume":"36","author":"D Caldwell","year":"2007","unstructured":"Caldwell D, Briggs A, Sculpher M, Claxton K. Int J Epidemiol. 2007;36(2):476\u20137. https:\/\/doi.org\/10.1093\/ije\/dym062.","journal-title":"Int J Epidemiol"},{"issue":"4","key":"13403_CR29","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/rheumatology\/keab522","volume":"61","author":"L Pina Vegas","year":"2022","unstructured":"Pina Vegas L, Le Corvoisier P, Penso L, Paul M, Sbidian E, Claudepierre P. Risk of major adverse cardiovascular events in patients initiating biologics\/apremilast for psoriatic arthritis: a nationwide cohort study. Rheumatology (Oxford). 2022;61(4):1589\u201399. https:\/\/doi.org\/10.1093\/rheumatology\/keab522.","journal-title":"Rheumatology (Oxford)"},{"issue":"Sep","key":"13403_CR30","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40257-023-00783-7","volume":"24","author":"PJ Mease","year":"2023","unstructured":"Mease PJ, Hatemi G, Paris M, et al. Apremilast long-term safety up to 5 years from 15 pooled randomized, placebo-controlled studies of psoriasis, psoriatic arthritis, and beh\u00e7et\u2019s syndrome. Am J Clin Dermatol. 2023;24(Sep):809\u201320. https:\/\/doi.org\/10.1007\/s40257-023-00783-7.","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"13403_CR31","first-page":"964","volume":"1","author":"J Udkoff","year":"2017","unstructured":"Udkoff J, Eichenfield LF. Cost-Effectiveness analysis of Ixekizumab vs etanercept and their Manufacturer-Recommended dosing regimens in moderate to severe plaque psoriasis. J Drugs Dermatol Oct. 2017;1(10):964\u201370.","journal-title":"J Drugs Dermatol Oct"},{"issue":"4","key":"13403_CR32","first-page":"423","volume":"24","author":"SJ Qi","year":"2024","unstructured":"Qi SJ, Xu Wei. Dupilumab injection in the treatment of moderate to severe atopic dermatitis in adults: a cost-effectiveness analysis. Chin J Evidence-Based Med. 2024;24(4):423\u20138.","journal-title":"Chin J Evidence-Based Med"},{"key":"13403_CR33","doi-asserted-by":"publisher","first-page":"1174879","DOI":"10.3389\/fpubh.2023.1174879","volume":"11","author":"W Zhang","year":"2023","unstructured":"Zhang W, Li L, Zhou Z, Liu Q, Wang G, Liu D. Cost-effectiveness of paxlovid in reducing severe COVID-19 and mortality in China. Front Public Health. 2023;11:1174879. https:\/\/doi.org\/10.3389\/fpubh.2023.1174879.","journal-title":"Front Public Health"},{"issue":"8","key":"13403_CR34","first-page":"45","volume":"41","author":"pL Li","year":"2024","unstructured":"Li pL, Li jm. Zou la, JI Yi z, Xiong mf. Study on hospitalization costs and influencing factors of chemotherapy patients with malignant tumor. Health Econ Res. 2024;41(8):45\u20138.","journal-title":"Health Econ Res"},{"issue":"6","key":"13403_CR35","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3969\/j.issn.1000-3614.2023.06.001","volume":"38","author":"China TWCotRoCHaDi","year":"2023","unstructured":"China TWCotRoCHaDi. Report on cardiovascular health and diseases in China 2022: an updated summary. Chin Circulation J. 2023;38(6):853\u2013612. https:\/\/doi.org\/10.3969\/j.issn.1000-3614.2023.06.001.","journal-title":"Chin Circulation J"},{"key":"13403_CR36","unstructured":"Yaozhidata.Bidding price. Accessed 5 Feb 2025, https:\/\/db.yaozh.com\/yaopinzhongbiao?comprehensivesearchcontent=Deucravacitinib&"},{"issue":"1","key":"13403_CR37","doi-asserted-by":"publisher","first-page":"2366503","DOI":"10.1080\/09546634.2024.2366503","volume":"35","author":"SH Park","year":"2024","unstructured":"Park SH, Lambton M, Schmier J, Hovland S, Wittstock K, Patel V. Cost per response analysis of Deucravacitinib versus Apremilast and first-line biologics among patients with moderate to severe plaque psoriasis in the United States. J Dermatolog Treat Dec. 2024;35(1):2366503. https:\/\/doi.org\/10.1080\/09546634.2024.2366503","journal-title":"J Dermatolog Treat Dec"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-13403-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-13403-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-13403-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:58:35Z","timestamp":1759229915000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-025-13403-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13403"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-13403-3","relation":{},"ISSN":["1472-6963"],"issn-type":[{"type":"electronic","value":"1472-6963"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This article is based on mathematical modeling with inputs informed primarily by previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1222"}}